Thioridazine: Alternative and potentially effective therapy of the XDRTB patient

Letters in Drug Design and Discovery

Volumn 8, Issue 2, 2011, Pages 130-132

  Amaral, Leonard ^a,b   Martins, Marta ^a,c   Viveiros, Miguel ^a,b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b Cost Action BM0701 ^*  (Portugal)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Macrophage activation; MDR TB; Phenothiazines; Therapy; Thioridazine; XDR TB

Indexed keywords

AMIKACIN; CAPREOMYCIN; CHLORPROMAZINE; ISONIAZID; KANAMYCIN; METHYLENE BLUE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIORIDAZINE;

ARTICLE; BACTERIAL STRAIN; COUGHING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; HUMAN; IN VITRO STUDY; INCREASED APPETITE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PSYCHOSIS; SHORT COURSE THERAPY; WEIGHT GAIN;

EID: 79952326503     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011794183860     Document Type: Article

References (30)

1. Amaral, L.; Martins, M.; Viveiros, M. Phenothiazines as anti-multidrug resistant tubercular agents. Infect. Disord. Drug Targets, 2007, 7(3), 257-265. (Pubitemid 350028059)
2. Russell, D.G. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol., 2007, 5, 39-47. (Pubitemid 44942302)
3. Viveiros, M.; Martins, M.; Couto, I.; Rodrigues, L.; Machado, D.; Portugal, I.; Amaral, L. Molecular tools for rapid identification and novel effective therapy against MDR/XDR-TB infections. Expert Rev. Anti-infect. Ther., 2010, 8(4), 465-480.
4. Ormerod, L.P. Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, prevention and treatment. Br. Med. Bull., 2005, 73-74(1), 17-24. (Pubitemid 43020355)
5. World Health Organization. Global tuberculosis control: Surveillance, planning, financing. WHO report 2008. World Health Organization, Geneva, Switzerland, 2008.
6. Stop TB Partnership. The Global Plan to Stop TB, 2006-2015: Actions for life: Towards a world free of tuberculosis. World Health Organization Geneva, Switzerland, 2006.
7. Perdigão, J.; Macedo, R.; João, I.; Fernandes, E.; Brum, L.; Portugal, I. Multidrug-resistant tuberculosis in Lisbon, Portugal: A molecular epidemiological perspective. Microb. Drug Resist., 2008, 14(2), 133-143.
8. Thanacoody, H.K. Thioridazine: Resurrection as an antimicrobial agent? Br. J. Clin. Pharmacol., 2007, 64(5) 566-574. (Pubitemid 47568829)
9. Amaral, L.; Viveiros, M.; Molnar, J. Antimicrobial activity of phenothiazines. In Vivo, 2004, 18(6), 725-732. (Pubitemid 40089621)
10. Ehrlich, P. The collected papers of Paul Ehrlich. In: Histology, Biochemistry and Pathology; Himmelweit, F.; Marquardi, M.; Dale, H.; Eds. London: Pergammon Press, 1956; Vol. 1, pp. 189- 194.
11. Amaral, L.; Viveiros, M.; Kristiansen, J.E. "Non-Antibiotics": Alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets, 2006, 7(7), 887-891.
12. Kaminska, M. Role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Med. Cracov., 1967, 9(1), 115-143.
13. Crowle, A.J.; Douvas, G.S.; May, M.H. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemother., 1992, 38(6), 410-419. (Pubitemid 23054943)
14. Amaral, L.; Kristiansen, J.E.; Viveiros, M.; Atouguia, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: A review supporting further studies that may elucidate the potential use of thioridazine as an anti-tuberculosis therapy. J. Antimicrob. Chemother., 2001, 47, 505-511. (Pubitemid 32447635)
15. Amaral, L.; Viveiros, M.; Kristiansen, J.E. Phenothiazines: Potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop. Med. Int. Health, 2001, 6(12), 1016-1022. (Pubitemid 34008769)
16. Frieden, T.R.; Fujiwara, P.I.; Washko, R.M.; Hamburg, M.A. Tuberculosis in New York City - turning the tide. N. Engl. J. Med., 1995, 333(4), 229-233.
17. Paolo, W.F. Jr.; Nosanchuk, J.D. Tuberculosis in New York city: Recent lessons and a look ahead. Lancet Infect. Dis., 2004, 4(5), 287-293. (Pubitemid 38561226)
18. Viveiros, M.; Amaral, L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents, 2001, 17(3), 225-228. (Pubitemid 32229901)
19. Amaral, L.; Kristiansen, J.E.; Abebe, L.S.; Millett, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother., 1996, 38, 1049-1053. (Pubitemid 27073284)
20. Ordway, D.; Viveiros, M.; Leandro, C.; Amaral, L. Clinical concentrations of Thioridazine kill intracellular Multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47(3), 917-922. (Pubitemid 36254216)
21. Amaral, L.; Martins, M.; Viveiros, M.; Molnar, J.; Kristiansen, J.E. Promising Therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr. Drug Targets, 2008, 9(9), 816-819.
22. Martins, M.; Viveiros, M.; Kristiansen, J.E.; Molnar, J.; Amaral, L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo, 2007, 21(5), 771-775.
23. Abbate, E.; Vescoso, M.; Natiello, M.; Cufre, M.; Garcia, A.; Ambroggi, M.; Poggi, S.; Simboli, N.; Ritacco, V. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Rev. Arg. Med. Respir., 2007, 7(1), 19-25.
24. Utwadia, Z.; Amaral, L. Therapy of unresponsive XDR-TB patients of Mumbai, India, to any current antibiotic regimen with thioridazine as the sole agent. 2010, In preparation.
25. Ratnakar, P.; Rao, S.P.; Sriramarao, P.; Murthy, P.S. Structureantitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int. Clin. Psychopharmacol., 1995, 10(1), 39-43.
26. Ahluwalia, J.; Tinker, A.; Clapp, L.H.; Duchen, M.R.; Abramov, A.Y.; Pope, S.; Nobles, M.; Segal, A.W. The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature, 2004, 427(6977), 853-858. (Pubitemid 38297748)
27. Martins, M.; Viveiros, M.; Couto, I.; Amaral, L. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. Tuberc. Lung Dis., 2009, 13(5), 569-573.
28. Martins, M.; Viveiros, M.; Amaral, L. The TB laboratory of the future: Macrophage-based selection of XDR-TB therapeutics. Future Microbiol., 2008, 3, 135-144. (Pubitemid 351984062)
29. Martins, M.; Schelz, Z.; Martins, A.; Molnar J.; Hajös, G.; Riedl, Z.; Viveiros, M.; Yalcin, I.; Amaral, L. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2007, 29(3), 338-340.
30. Amaral, L.; Boeree, M.; Gillespie, S.H.; Udwadia, Z.; van Soolingen, D. Thioridazine cures cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int. J. Antimicrob. Agents, 2010, 35(6), 524-526.